Preferred diuretic therapy for primary hypertension: Chlorthalidone or hydrochlorothiazide?

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Chlorthalidone is recommended over hydrochlorothiazide for primary hypertension due to superior reduction in major adverse cardiovascular events (MACE).
• Despite recommendations, hydrochlorothiazide remains more commonly prescribed than chlorthalidone.
• A discrepancy exists between guideline recommendations and clinical practice regarding diuretic choice for hypertension management.

Purpose of the Study:

• To review recent studies comparing the effectiveness of chlorthalidone and hydrochlorothiazide in reducing MACE.
• To provide clinicians with evidence-based information to guide diuretic selection for primary hypertension.
• To address the gap between recommended and prescribed diuretics for hypertension.

Main Methods:

• Systematic review of recent clinical studies.
• Analysis of data on MACE reduction associated with chlorthalidone and hydrochlorothiazide.
• Comparative effectiveness research on antihypertensive diuretics.

Main Results:

• Studies indicate chlorthalidone demonstrates a greater reduction in MACE compared to hydrochlorothiazide.
• Evidence supports the preferential use of chlorthalidone for cardiovascular risk reduction in hypertensive patients.
• Recent research reinforces the guideline recommendation for chlorthalidone over hydrochlorothiazide.

Conclusions:

• Chlorthalidone is the preferred diuretic for primary hypertension due to its proven efficacy in reducing MACE.
• Clinicians should consider recent evidence favoring chlorthalidone to optimize cardiovascular outcomes.
• Prescribing patterns should align with evidence-based recommendations for improved hypertension management and MACE prevention.